Full Paper Title: Patient-Reported Outcomes in a Phase II Trial of Ruxolitinib and Pembrolizumab for Relapsed or Refractory Peripheral and Cutaneous T-cell Lymphomas
Disclosure: No relevant conflicts of interest to declare.
Join us for this special session highlighting the research of ASH Hematology Inclusion Pathway (HIP) awardees. The HIP initiative is a comprehensive, 13-year longitudinal career pathway designed to ensure that the field of hematology reflects and serves the diverse world we live in. The session will feature oral scientific presentations from current program awardees, highlighting their innovative work and contributions to the field, with a focus on Malignant Hematology. Following the presentations, we welcome you to connect with the HIP community and celebrate our awardees and their mentors at a networking reception.
